PROLIGHT DIAGNOSTICS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.15 SEK | +4.17% |
|
+23.97% | -50.17% |
| May. 17 | Prolight Diagnostics Gets SEK17 Million Grant to Advance Product Development | MT |
| May. 17 | Prolight Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 119.5 | 255.1 | 357.9 | 152.1 | 54.76 | 149.7 |
| Enterprise Value (EV) 1 | 98.55 | 239.7 | 306.7 | 108.2 | 0.6495 | 136.4 |
| P/E ratio | -17.4 x | -50.1 x | -75.4 x | -22.2 x | - | -0.63 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 296 x | 1,568 x | 434 x | 1,414 x | 1.55 x | 6.18 x |
| EV / Revenue | 244 x | 1,473 x | 372 x | 1,006 x | 0.02 x | 5.63 x |
| EV / EBITDA | - | - | - | - | -51,908 x | -1,009,948 x |
| EV / FCF | -2.97 x | -8.89 x | -15.8 x | -22.9 x | -0.02 x | -1.51 x |
| FCF Yield | -33.7% | -11.2% | -6.33% | -4.37% | -5,461% | -66.4% |
| Price to Book | 1.48 x | 2.53 x | 2.34 x | 1.04 x | 0.27 x | 0.78 x |
| Nbr of stocks (in thousands) | 94,826 | 126,299 | 149,104 | 149,104 | 282,269 | 497,212 |
| Reference price 2 | 1.260 | 2.020 | 2.400 | 1.020 | 0.1940 | 0.3010 |
| Announcement Date | 4/9/19 | 4/2/20 | 4/14/21 | 4/29/22 | 4/20/23 | 4/30/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.404 | 0.1627 | 0.8246 | 0.1075 | 35.27 | 24.22 |
| EBITDA | - | - | - | - | -12.51 | -135 |
| EBIT 1 | -5.811 | -4.366 | -4.181 | -6.951 | -12.65 | -135.8 |
| Operating Margin | -1,438.55% | -2,683% | -507.1% | -6,464.07% | -35.86% | -560.88% |
| Earnings before Tax (EBT) 1 | -5.857 | -4.132 | -4.3 | -6.855 | -12.28 | -135.5 |
| Net income 1 | -5.857 | -4.132 | -4.3 | -6.855 | -12.28 | -135.5 |
| Net margin | -1,449.89% | -2,539.46% | -521.55% | -6,374.51% | -34.8% | -559.41% |
| EPS 2 | -0.0722 | -0.0403 | -0.0318 | -0.0460 | - | -0.4790 |
| Free Cash Flow 1 | -33.17 | -26.95 | -19.43 | -4.73 | -35.47 | -90.52 |
| FCF margin | -8,210.71% | -16,561.26% | -2,356.19% | -4,398.58% | -100.58% | -373.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/9/19 | 4/2/20 | 4/14/21 | 4/29/22 | 4/20/23 | 4/30/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 20.9 | 15.5 | 51.1 | 43.9 | 54.1 | 13.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -33.2 | -26.9 | -19.4 | -4.73 | -35.5 | -90.5 |
| ROE (net income / shareholders' equity) | -9.89% | -4.52% | -3.39% | -4.58% | -6.98% | -80.1% |
| ROA (Net income/ Total Assets) | -5.89% | -2.87% | -2.02% | -2.86% | -4.43% | -45% |
| Assets 1 | 99.42 | 144 | 212.5 | 239.4 | 277.2 | 300.9 |
| Book Value Per Share 2 | 0.8500 | 0.8000 | 1.030 | 0.9800 | 0.7300 | 0.3800 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.3400 | 0.2900 | 0.1900 | 0.0400 |
| Capex | - | - | - | - | 0.79 | 2.8 |
| Capex / Sales | - | - | - | - | 2.25% | 11.58% |
| Announcement Date | 4/9/19 | 4/2/20 | 4/14/21 | 4/29/22 | 4/20/23 | 4/30/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -50.17% | 7.19M | |
| -39.63% | 8.41B | |
| +7.43% | 3.82B | |
| +0.38% | 2.33B | |
| -21.06% | 2.02B | |
| -22.03% | 1.67B | |
| +29.47% | 1.14B | |
| +28.58% | 760M | |
| -9.39% | 697M | |
| -20.41% | 566M |
- Stock Market
- Equities
- PRLD Stock
- Financials Prolight Diagnostics AB
